stockrow
Friday 6 November 2026
Export CSTL’s income statement to Excel — free account
Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024.
- Revenue
- +23.9%
- EPS
- −550.0%
- Free cash flow
- +56.8%
- Total debt
- −59.9%
Quarter to September 2026, against a year earlier
32.65
1.55
−4.53%
Follow CSTL
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.89 | 2.03 | 2.16 | 3.28 | |
P/FCF ratio |
272.85 | 0.00 | 160.88 | 39.74 | |
P/Operating CF |
55.13 | 47.70 | (33.16) | 41.87 | |
P/B ratio |
2.27 | 1.54 | 1.59 | 2.39 | |
Price to Tangible BV |
2.81 | 1.93 | 2.02 | 3.04 | |
EV/Sales |
2.21 | 1.31 | 1.42 | 2.44 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
20.96 | 10.99 | 10.00 | 13.03 | |
EV/FCF |
208.87 | (1,036.62) | 105.78 | 29.55 | |
Quick Ratio |
0.77 | 5.58 | 6.23 | 4.99 | |
Current Ratio |
5.28 | 6.04 | 6.75 | 5.26 | |
Net Debt/EBITDA |
3.77 | (421.82) | 16.83 | 381.44 | |
Debt/Assets |
0.72% | 1.84% | 1.89% | 1.79% | |
Debt/Equity |
0.01 | 0.02 | 0.02 | 0.02 | |
Asset Turnover |
0.66 | 0.65 | 0.65 | 0.62 | |
Operating CF/Net income |
(4.81) | (7.38) | 1.52 | (11.55) | |
Capex/Depreciation |
(1.95) | (2.35) | (3.58) | (2.34) | |
Interest Coverage |
(13.86) | (15.91) | (137.37) | (159.46) | |
Research and Development Expense of Revenue |
15.36% | 14.04% | 17.24% | 15.53% | |
Selling, General and Administrative Expense of Revenue |
62.00% | 63.86% | 77.56% | 65.20% | |
Intangible Assets out of Total Assets |
0.16 | 0.17 | 0.18 | 0.17 | |
Share Based Compensation of Revenue |
10.92% | 11.19% | 11.68% | 13.11% | |
Graham Net Nets |
0.24 | 0.34 | 0.33 | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.17%) | (2.77%) | (1.75%) | (2.16%) | |
Free Cash Flow Yield |
0.37% | (0.06%) | 0.62% | 2.52% | |
Revenue per Share |
3.36 | 3.41 | 2.80 | 3.00 | |
Operating CF per Share |
0.64 | 0.50 | (0.74) | 0.93 | |
Capex per Share |
(0.24) | (0.28) | (0.42) | (0.25) | |
Free Cash Flow per Share |
0.40 | 0.22 | (1.16) | 0.68 | |
Cash per Share |
0.00 | 8.78 | 8.76 | 10.33 | |
Shareholders Equity per Share |
15.62 | 15.46 | 15.44 | 16.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.62 | 15.46 | 15.44 | 16.24 | |
Free Cash Flow |
12.26 | 6.56 | (34.58) | 19.75 | |
Working Capital |
289.25 | 284.59 | 280.14 | 292.42 | |
Capital Expenditures |
(7.48) | (8.64) | (12.45) | (7.18) | |
Net Current Asset Value |
255.89 | 249.95 | 242.51 | 253.41 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.07 | 0.08 | 0.15 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
50.79 | 50.33 | 49.31 | 47.30 | |
Average Payables |
12.72 | 11.42 | 11.77 | 12.81 | |
Average Inventory |
9.52 | 9.47 | 8.66 | 9.19 | |
Average Assets |
571.10 | 552.95 | 524.76 | 554.90 | |
Average Common Equity |
472.75 | 462.70 | 450.86 | 463.35 |
Columns are period end dates · fundamentals updated 5 Nov 2026